Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE DF 2156A is a new dual inhibitor of IL‐8 receptors CXCR1 and CXCR2 with an optimal pharmacokinetic profile. We characterized its binding mode, molecular mechanism of action and selectivity, and evaluated its therapeutic potential. EXPERIMENTAL APPROACH The binding mode, molecular mechanism of action and selectivity were investigated using chemotaxis of L1.2 transfectants and human leucocytes, in addition to radioligand and [35 S]‐GTPγS binding approaches. The therapeutic potential of DF 2156A was evaluated in acute (liver ischaemia and reperfusion) and chronic (sponge‐induced angiogenesis) experimental models of inflammation. KEY RESULTS A network of polar interactions stabilized by a direct ionic bond between DF 2156A and Lys 99 on CXCR1 and the non‐conserved residue Asp 293 on CXCR2 are the key determinants of DF 2156A binding. DF 2156A acted as a non‐competitive allosteric inhibitor blocking the signal transduction leading to chemotaxis without altering the binding affinity of natural ligands. DF 2156A effectively and selectively inhibited CXCR1/CXCR2‐mediated chemotaxis of L1.2 transfectants and leucocytes. In a murine model of sponge‐induced angiogenesis, DF 2156A reduced leucocyte influx, TNF‐α production and neovessel formation. In vitro, DF 2156A prevented proliferation, migration and capillary‐like organization of HUVECs in response to human IL‐8. In a rat model of liver ischaemia and reperfusion (I/R) injury, DF 2156A decreased PMN and monocyte‐macrophage infiltration and associated hepatocellular injury. CONCLUSION AND IMPLICATIONS DF 2156A is a non‐competitive allosteric inhibitor of both IL‐8 receptors CXCR1 and CXCR2. It prevented experimental angiogenesis and hepatic I/R injury in vivo and, therefore, has therapeutic potential for acute and chronic inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889
Intravascular Danger Signals Guide Neutrophils to Sites of Sterile Inflammation
McDonald, B., Pittman, K., Menezes, G. B., Hirota, S. A., Slaba, I., Waterhouse, C. C. M., Beck, P. L., Muruve, D. A., & Kubes, P. (2010) · Science · doi:10.1126/science.1195491 · Cited by 1,210
Phagocyte partnership during the onset and resolution of inflammation
Soehnlein, O., & Lindbom, L. (2010) · Nature Reviews Immunology · doi:10.1038/nri2779 · Cited by 1,054 · cited 1×
“Moreover, it was recently demonstrated that PMN-derived granule proteins cathepsin G, LL-37 and azurocidin attract monocytes, this effect being mediated by FPRs receptors (Soehnlein and Lindbom, 2010).”
BackgroundDelayed Wound Healing in CXCR2 Knockout Mice
Devalaraja, R. M., Nanney, L. B., Qian, Q., Du, J., Yu, Y., Devalaraja, M. N., & Richmond, A. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00034.x · Cited by 429 · cited 1×
“Accordingly, Devalaraja et al. (2000) showed decreased angiogenesis and PMN recruitment in the skin wound healing model using CXCR2deficient mice, although the role of CXCR1 remains to be elucidated.”
BackgroundHuo, Y., Weber, C., Forlow, S. B., Sperandio, M., Thatte, J., Mack, M., Jung, S., Littman, D. R., & Ley, K. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12877 · Cited by 266
Cited by
Neutrophil migration in infection and wound repair: going forward in reverse
de Oliveira, S., Rosowski, E. E., & Huttenlocher, A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.49 · Cited by 1,058
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Ha, H., Debnath, B., & Neamati, N. (2017) · Theranostics · doi:10.7150/thno.15625 · Cited by 789
The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases
Russo, R. C., Garcia, C. C., Teixeira, M. M., & Amaral, F. A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.894886 · Cited by 647
Self-citationMarques, P. E., Amaral, S. S., Pires, D. A., Nogueira, L. L., Soriani, F. M., Lima, B. H. F., Lopes, G. A. O., Russo, R. C., Ávila, T. V., Melgaço, J. G., et al. (2012) · Hepatology · doi:10.1002/hep.25801 · Cited by 332
Self-citationIL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis
Gross, A. C., Cam, H., Phelps, D. A., Saraf, A. J., Bid, H. K., Cam, M., London, C. A., Winget, S. A., Arnold, M. A., Brandolini, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99791 · Cited by 82
Metadata
- Authors
- Bertini, R., Barcelos, L., Beccari, A., Cavalieri, B., Moriconi, A., Bizzarri, C., Di Benedetto, P., Di Giacinto, C., Gloaguen, I., Galliera, E., Corsi, M., Russo, R., Andrade, S., Cesta, M., Nano, G., Aramini, A., Cutrin, J., Locati, M., Allegretti, M., & Teixeira, M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-12-16
- Volume
- 165
- Issue
- 2
- Pages
- 436-454
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1605318550
- Cited by
- 74
- References
- 5
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01566.x
- The paper
- Bertini, R., Barcelos, L., Beccari, A., Cavalieri, B., Moriconi, A., Bizzarri, C., Di Benedetto, P., Di Giacinto, C., Gloaguen, I., Galliera, E., Corsi, M., Russo, R., Andrade, S., Cesta, M., Nano, G., Aramini, A., Cutrin, J., Locati, M., Allegretti, M., & Teixeira, M. (2012). Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01566.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.